Dashboard
1
Poor Management Efficiency with a low ROCE of 0.38%
- The company has been able to generate a Return on Capital Employed (avg) of 0.38% signifying low profitability per unit of total capital (equity and debt)
2
Poor long term growth as Net Sales has grown by an annual rate of 21.35% and Operating profit at -285.37% over the last 5 years
3
Risky -
Stock DNA
Pharmaceuticals & Biotechnology
CNY 3,775 Million (Mid Cap)
NA (Loss Making)
NA
0.00%
0.08
-5.52%
3.86
Revenue and Profits:
Net Sales:
168 Million
(Quarterly Results - Dec 2025)
Net Profit:
-36 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0.99%
0%
0.99%
6 Months
6.42%
0%
6.42%
1 Year
56.03%
0%
56.03%
2 Years
-4.68%
0%
-4.68%
3 Years
42.48%
0%
42.48%
4 Years
20.73%
0%
20.73%
5 Years
-17.56%
0%
-17.56%
Jiangsu Aidea Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
21.35%
EBIT Growth (5y)
-285.37%
EBIT to Interest (avg)
-26.07
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.06
Sales to Capital Employed (avg)
0.30
Tax Ratio
15.76%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0.38%
ROE (avg)
0.68%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
6.10
EV to EBIT
-68.17
EV to EBITDA
-219.95
EV to Capital Employed
5.69
EV to Sales
10.37
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-8.35%
ROE (Latest)
-8.32%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
168.30
189.90
-11.37%
Operating Profit (PBDIT) excl Other Income
19.30
-0.70
2,857.14%
Interest
0.00
3.80
-100.00%
Exceptional Items
0.00
-5.90
100.00%
Consolidate Net Profit
-35.80
-10.40
-244.23%
Operating Profit Margin (Excl OI)
114.50%
-3.90%
11.84%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is -11.37% vs 15.37% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is -244.23% vs -1,255.56% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
720.70
412.20
74.84%
Operating Profit (PBDIT) excl Other Income
47.70
-94.90
150.26%
Interest
0.00
15.50
-100.00%
Exceptional Items
0.00
-18.20
100.00%
Consolidate Net Profit
-19.70
-138.80
85.81%
Operating Profit Margin (Excl OI)
66.30%
-367.70%
43.40%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 74.84% vs 0.78% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 85.81% vs -82.39% in Dec 2024
About Jiangsu Aidea Pharmaceutical Co., Ltd. 
Jiangsu Aidea Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






